



Updated Monthly
September 9, 2025

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com

  @G2Gconsulting





TABLE OF CONTENTS

New Opportunities

Aging.....	2
Amyotrophic Lateral Sclerosis	2
Artificial Intelligence & Machine Learning	3
Autoimmune Diseases	3
Biomedical Research.....	4
Biotechnology and Biomanufacturing.....	5
Cancer	6
Cardiovascular and Pulmonary Health.....	7
Chronic Pain & Pain Management	7
Cognitive and Brain Health.....	7
Combat Casualty Care.....	9
Digestive Diseases.....	10
Energy Science	10
Genomics	11
Health Equity	11
HIV/AIDS	11
Immunology & Infectious Disease	12
Interception Research.....	14
Mental Health.....	15
NIH Common Fund.....	15

GBG Report

Updated Monthly

September 10, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

Pediatric Health.....	15
Regenerative Medicine.....	16
Research Support	16
Small Business Development	16
Substance Use Disorder	17
Therapeutics.....	17

Recurring Opportunities

Advanced Research Projects Agency for Health.....	19
Air Force	20
Army.....	21
BARDA	23
DARPA	23
Defense Threat Reduction Agency	23
Department of Energy	24
National Science Foundation	25
Navy	25
Office of the Undersecretary of Defense	26
Patient-Centered Outcomes Research Institute	26

GBG Acronyms	28
--------------------	----



September 18, 2025 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, NMBio, Ohio Life Sciences, South Dakota Biotech, VaBio, or WVBio – your membership gets you access to the [private consultation meeting](#).

Women’s Health – G2G’s Liz Powell leads the [Women’s Health Advocates](#), and will be speaking all over the country in September and October. [Join the community](#) if you’d like to keep up with her schedule.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (1)		
1.	Aging Mammalian Tissues In Vitro (R21 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-26-014	This NOFO invites applications that propose interdisciplinary research that aims to develop complex mammalian 3-dimensional (3D) in vitro microphysiological systems (MPS) to model aging and recapitulate aging processes/phenotypes observed in the whole organism in vivo. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-014.html	Up to \$275,000, for up to 2 years	Proposal: 10/20/25
		AMYOTROPHIC LATERAL SCLEROSIS (1)		
2.	Forecast: Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (NIH/NINDS) RFA-NS-26-001	Individuals with ALS may enroll in ongoing phase 3/efficacy clinical trials of investigational drugs and biological products for ALS. However, inclusion criteria often restrict participation to only a subset of people with ALS. EA was established to provide treatment access to investigational medical products for people with serious, life-threatening diseases like ALS when no comparable or satisfactory therapy is available to diagnose, monitor, or treat the disease or condition. This pathway is defined and regulated by the FDA. To be eligible, EA protocols should generate data to support research on the prevention, diagnosis, mitigation, treatment, or cure of ALS. https://www.grants.gov/search-results-detail/360400	Total funding of \$40 million	Estimated post date: 10/29/25 Estimated proposal date: 11/28/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (3)		
3.	Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU) (EU) HORIZON-HLTH-2025-01-TOOL-03	This topic will contribute to advancing research and providing new evidence on how Generative AI models contribute to and support biomedical research and its applicability towards more predictive and personalised medicine, while also defining use conditions, usability requirements and training needs of the researchers. It aims to cover existing gaps related to Generative AI in biomedical research, addressing both capabilities and existing limitations. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-TOOL-03	Total funding of €50 million	Proposal: 9/16/25
4.	Foundations for Operating the National Artificial Intelligence Research Resource: the NAIRR Operations Center (NAIRR-OC) (NSF) NSF 25-546	This solicitation seeks proposals to establish a community-based organization that will be responsible for the foundational visioning, coordination, operations, and development activities in support of an integrated national infrastructure for AI research and education. https://www.nsf.gov/funding/opportunities/nairr-oc-foundations-operating-national-artificial-intelligence/nsf25-546/solicitation	Dependent upon proposal and availability of funds	Letter of intent: 12/15/25 Proposal: 2/4/26
5.	Critical Technology Challenge: AI and Digital Transformation (TechConnect)	The Challenge is an open innovation program focused on accelerating breakthrough technologies in alignment with evolving strategic priorities for national security, economic resilience, and technological modernization. Areas of interest include: Applied AI and machine learning solutions; Autonomous systems and decision-support tools; Human-machine teaming and intelligent interfaces; and AI for operations, logistics, and supply chain resilience. https://www.techconnectworld.com/World2026/CTC_AI/	Opportunity to pitch at conference in March 2026	Proposal: 10/24/25
		AUTOIMMUNE DISEASES (1)		
6.	NOURISH (Nutrition for OUR Immune System Health): Autoimmunity Challenge (NIH)	NOURISH is a crowdsourcing competition focused on generating a cadre of innovative ideas on how to best integrate diet and nutrition studies into autoimmune disease research with a focus on identifying dietary interventions that are feasible, testable, scalable, and will have broad impact across the broad autoimmune disease portfolio. NIH is seeking ideas for new ways of studying diet and nutrition in autoimmune disease research, including the role diet plays in the autoimmune prodrome and autoimmune disease inception, how diet and nutrition contribute to autoimmune disease progression and flares, and the role that diet may play in symptom management. https://www.challenge.gov/?challenge=nourish-autoimmunity-challenge	Total prizes of \$150,000	Submission window: 9/23-12/4/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH (4)		
7.	RFI: Energy harvesting implantable health monitoring solutions (DoD/DARPA) DARPA-SN-25-96	We are interested in exploring all feasible energy harvesting technologies suitable for implantable medical devices. The goal is to identify solutions capable of providing continuous, reliable power to enable advanced implantable functionalities. https://sam.gov/workspace/contract/opp/9d2bb2f50d7348fca6353c63a4424529/view	N/A	Response: 9/22/25
8.	Tackling high-burden for patients and under-researched medical conditions (EU) HORIZON-HLTH-2025-01-DISEASE-07	A number of medical conditions fail to be recognised and/or be correctly diagnosed in a significant proportion of patients. As a consequence, they are inadequately treated and often can become a chronic and high burden for the patient. These medical conditions, including: myalgic encephalomyelitis/chronic fatigue syndrome, autism, gynaecological diseases, low back pain, and other; may be insufficiently researched even though they manifest with high prevalence. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-DISEASE-07	Total funding of €30 million	Proposal: 9/16/25
9.	Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices (EU) HORIZON-HLTH-2025-03-IND-03-two-stage	The focus of this topic is on multinational clinical studies of orphan devices and/or of highly innovative devices, including digital and AI based tools and techniques. Orphan devices are specifically intended for use in rare diseases or conditions or in specific indications for rare cohorts of patients with an otherwise non-rare disease or condition. As, by their nature, orphan devices are intended for use in a small number of individuals each year, often infants and children, generating clinical data within an appropriate period of time and conducting clinical investigations is especially challenging due to low patient recruitment volumes. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-03-IND-03-two-stage	Total funding of €40 million	Proposal: 9/16/25
10.	Forecast: Biomedical Technology Optimization and Dissemination Center (BTOD) (NIH/NIGMS) PAR-26-028	This program supports optimization of late-stage technologies that have demonstrated laboratory feasibility. The centers will move the technologies to the point where they can be widely used and will promote their dissemination within the biomedical research community. https://www.grants.gov/search-results-detail/360446	TBD	Estimated post date: 2/28/26 Estimated proposal date: 5/28/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOTECHNOLOGY AND BIOMANUFACTURING (4)		
11.	Expedited Research Innovation System (ERIS) (DoD/DARPA) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats, human-made or naturally occurring; Advanced technologies for the improved resilience of US operations throughout the prepare, deployment, execute, and return cycle; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems, going beyond the limitations of current reductive scientific methods. https://sam.gov/workspace/contract/opp/fabda3a3d150457d97068977672ec750/view	Dependent upon proposal and award mechanism	Proposal: 5/30/26
12.	Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs) (EU) HORIZON-HLTH-2025-01-IND-01	The topic focuses on addressing the challenges of ATMP manufacturing, the need for highly specialised equipment and facilities, including in-process quality control and validation tests, scaling up and batch-to-batch reproducibility, whilst maintaining the efficacy of an ATMP product during the manufacturing process and/or the transition from centralised to decentralised manufacturing. This topic aims to optimise the ATMP production where the general manufacturing process for a given medicinal product has already been established but has not been sufficiently optimised for its scale-up. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-IND-01	Total funding of €40 million	Proposal: 9/16/25
13.	Critical Technology Challenge: Biotech and Medical (TechConnect)	The Challenge is an open innovation program focused on accelerating breakthrough technologies in alignment with evolving strategic priorities for public health, national security, and medical resilience. In 2026, the spotlight is on biotech and medical innovation, showcasing advances in diagnostics, therapeutics, bioengineering, digital health, and medical readiness. Areas of interest include Next-generation diagnostics and biosensors; Advanced therapeutics and delivery systems; Synthetic biology and bioengineering platforms; Medical devices, wearables, and remote monitoring; Biomanufacturing and lab automation; Digital health and AI-enabled care solutions; Preparedness and response technologies; Personalized medicine and precision health; Regenerative medicine and cell/gene therapies; and other transformative biotech and medical innovations. https://www.techconnectworld.com/World2026/CTC_Biotech_Medical/	Opportunity to pitch at conference in March 2026	Proposal: 10/24/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOTECHNOLOGY AND BIOMANUFACTURING		
14.	Critical Technology Challenge: Advanced Materials (TechConnect)	The Challenge is an open-innovation program focused on accelerating breakthrough technologies in alignment with evolving strategic priorities for national security, sustainability, and economic resilience. In 2026, the spotlight is on advanced materials, showcasing innovations in novel compounds, sustainable solutions, next-gen coatings, nanomaterials, and more. Areas of interest include biomaterials and biofabrication https://www.techconnectworld.com/World2026/CTC_Advanced_Materials/	Opportunity to pitch at conference in March 2026	Proposal: 10/24/25
		CANCER (3)		
15.	Forecast: Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional) (NIH/NCI) PAR-25-454	The CPACH Program develops and maintains comprehensive, long-term, mutually beneficial partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and addresses challenges in cancer research, including a focus on advancing research on health drivers that contribute to differences in cancer outcomes across all populations, as well as cancer outreach and engagement. https://www.grants.gov/search-results-detail/360393	Total funding of \$850,000	Estimated post date: 11/28/25 Estimated proposal date: 1/19/26
16.	Forecast: Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-26-001	This NOFO will solicit grant applications proposing to develop innovative technologies for analyzing, targeting, probing, handling, or quality control of biospecimens used in cancer research or clinical care. The emphasis of this NOFO is on early-stage projects proposing proof-of-concept/pilot studies to test the feasibility of the proposed method, tool, assay, platform, or instrument. Well-suited applications must offer a high degree of technical innovation and the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology, and/or address issues associated with cancer health disparities. https://www.grants.gov/search-results-detail/360536	Up to \$150,000	Estimated post date: 11/30/25 Estimated proposal date: 4/10/26
17.	Forecast: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-26-002	This NOFO will solicit grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. https://www.grants.gov/search-results-detail/360534	Up to \$150,000	Estimated post date: 11/30/25 Estimated proposal date: 4/10/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH (1)		
18.	Forecast: HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional) (NIH/NHLBI) RFA-HL-26-026	The CTC will coordinate precision clinical trial activities focused on heart failure with preserved ejection fraction (HFpEF). The CCs will recruit and retain heart failure patients and controls. CCs will participate in all aspects of conducting a deep phenotyping protocol and longitudinal follow-up of HFpEF patients; obtaining tissue biopsies; and interpreting and translating results in addition to supporting future clinical trials. https://www.grants.gov/search-results-detail/360439	TBD	Estimated post date: 10/15/26 Estimated proposal date: 12/15/26
		CHRONIC PAIN & PAIN MANAGEMENT (1)		
19.	Forecast: HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) (NIH) RFA-NS-25-031	This NOFO will solicit applications for the conduct of large-scale, multisite clinical trials (CTs) that will inform clinicians about the efficacy or effectiveness of interventions or management strategies that reduce opioid use, improve functional outcomes and reduce pain across the continuum of acute to chronic pain associated with many types of diseases, conditions, or pain presenting as a disease itself. https://www.grants.gov/search-results-detail/360385	TBD	Estimated post date: 10/15/25 Estimated proposal date: 1/5/26
		COGNITIVE AND BRAIN HEALTH (10)		
20.	Forecast: Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's and Related Dementias Disease Risk (NIH/NIA) PAR-26-067	The goal of this NOFO is to build a robust program that integrates epidemiologic, genomic, and mechanistic research through the use of data driven, systems-based approaches (including the use of artificial intelligence and/or machine learning methods) to discover the molecular/cellular determinants of resilience to AD/ADRD risk across representative populations. The initiative will support the generation of high-dimensional molecular data from brain and peripheral tissues, including longitudinal data, to enable dynamic modeling of resilience mechanisms and to discover molecular predictors of resilience. https://www.grants.gov/search-results-detail/360453	TBD	Estimated post date: 2/26/26 Estimated proposal date: 6/5/26
21.	Forecast: NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required) (NIH/NINDS) PAR-26-069	This NOFO will to solicit applications for research on exploratory and efficacy clinical trials that address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. https://www.grants.gov/search-results-detail/360404	TBD	Estimated post date: 11/12/25 Estimated proposal date: 2/10/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
22.	Forecast: Translational Center for Accelerating the Use of Digital Health Technologies Data in AD/ADRD Research (NIH/NIA) RFA-AG-27-002	The purpose of the Center is to develop infrastructure, methods, and best practices for hosting, discovering, accessing, disseminating, and integrating multi-modal, legacy, and new DHT data, and accelerate their (re)use in translational and clinical AD/ADRD research. To this end, the Center will establish a DHT data repository as a cloud-based; federated; FAIR data infrastructure for the secure storage, processing, dissemination, analysis, and multi-modal integration of legacy and new DHT data generated by AD/ADRD studies supported by NIH and other funding organizations. https://www.grants.gov/search-results-detail/360451	TBD	Estimated post date: 2/27/26 Estimated proposal date: 5/25/26
23.	Forecast: BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (U01 BESH Required) (NIH) RFA-NS-26-007	This NOFO will solicit applications for research on investigative neuroscience with intracranial access to recording and manipulating the brain directly. Investigations within the human brain offer revolutionary, but challenging, opportunities for experimental investigation in how the human brain senses, perceives, remembers, plans, makes decisions, registers emotions, engages language, and activates movements. https://www.grants.gov/search-results-detail/360402	TBD	Estimated post date: 11/28/25 Estimated proposal date: 2/27/26
24.	Forecast: Collaborative Opportunities for Multiple-disciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional) (NIH/NINDS) RFA-NS-26-009	This NOFO will solicit applications from highly-integrated transdisciplinary team science led by 3-6 PDs/PIs to pursue a single focused goal to overcome persistent barriers, challenge orthodoxies, achieve paradigm-shifts, or develop new foundational principles in neuroscience. Within five-years, the team must deliver outcomes significantly advancing the NINDS mission and transform knowledge and practice, ranging from fundamental neuroscience to human health. https://www.grants.gov/search-results-detail/360396	TBD	Estimated post date: 2/4/26 Estimated proposal date: 6/23/26
25.	Forecast: BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iTeamBCP (RM1 Clinical Trial Optional) (NIH) RFA-NS-26-011	This NOFO will to solicit applications from teams to understand how the nervous system, from its individual components to its unified whole, gives rise to mental experience and behavior. Teams must integrate distinct expertise to deliver fundamental principles about CNS function through theories, models, and approaches that bridge cells, circuits, behavior. Applications must connect these 3 levels of analysis: (1) rich large-scale information about circuit components, (2) in vivo CNS recordings at cellular and sub-second and temporal resolution, (3) along with analyses of a tractable behavior of an organism or a well-defined neural system. https://www.grants.gov/search-results-detail/360398	TBD	Estimated post date: 2/4/26 Estimated proposal date: 6/16/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
26.	Forecast: Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection – Network Sites and Coordinating Center (U01- CT Not Allowed) (NIH/NINDS) RFA-NS-26-012	This NOFO will solicit applications for the Coordinating Center and Testing Sites of the Stroke Preclinical Assessment Network (SPAN), a preclinical network to support translational studies for cerebroprotection in experimental models of acute ischemic stroke. https://www.grants.gov/search-results-detail/360432	Total funding of \$500,000	Estimated post date: 12/17/25 Estimated proposal date: 3/18/26
27.	Neuroimaging and CSF Biomarker Program (ADDF)	The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in AD/ADRD. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use. https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers	Up to \$600,000, for up to 1 year, with potential for follow-on funding	Letter of intent: 9/15/25 Invited proposal: 11/17/25
28.	Prevention (ADDF)	The ADDF seeks to support precision prevention studies, combination therapy studies, and comparative effectiveness research that probe whether the use or choice of interventions may reduce the risk of AD/ADRD. Studies that are not in humans will not be considered. https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-pipeline	Up to \$5 million	Letter of intent: 9/15/25 Invited proposal: 11/17/25
29.	Drug Development (ADDF)	The Drug Development RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for AD/ADRD. This funding opportunity concentrates on diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-rfp	Up to \$5 million	Letter of intent: 9/15/25 Invited proposal: 11/17/25
		COMBAT CASUALTY CARE (2)		
30.	2025 Joint Innovation Medical Symposium (JIMS) (DoD/Army) JIMS_2025	The goal of the JIMS is to create partnerships between Special Operations Forces (SOF) and industry to accelerate SOF's technical advantage in the medical arena. TTIs include, but are not limited to: Patient warming system; EMP hardening of electronic medical devices; and Non-Compressible hemorrhage mitigation. https://vulcan-sof.com/login/ng2/submission?collectionUuid=6f1de8d6-9eb2-42e1-aa92-bb0dcd390c9d	Dependent upon proposal	Proposal: 9/28/25 Event is 11/3-6/25 at Fort Bragg, NC



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COMBAT CASUALTY CARE		
31.	Pre-Announcement: "Advanced Medical Monitor" (MTEC)	The upcoming RPP is focused on developing Advanced Medical Monitor (AMM) Family of systems (FoS) components, including the Next Generation Medical Monitor (NGMM) and the Expeditionary Medical Monitor (EMM), which continuously track vital signs and other relevant data. Both devices must be designed for expeditionary medical use and easy to maintain. The desired prototypes, by their final design, will need to be capable of advanced noninvasive physiological monitoring to provide actionable information for enhanced military patient triage, to reduce cognitive workload, to inform treatment and evacuation priorities, as well as monitor vital signs of patients under medical care. https://mtec-sc.org/solicitations/advanced-medical-monitor	Up to \$4 million, for up to 2 years	TBD
		DIGESTIVE DISEASES (2)		
32.	Forecast: Silvio O. Conte Digestive Diseases Research Core Centers (NIH/NIDDK) RFA-DK-27-119	The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. https://www.grants.gov/search-results-detail/360436	TBD	Estimated post date: 4/1/26 Estimated proposal date: 7/27/26
33.	AGA Incubator: Improving GI Care (AGA)	These disparities underscore the need for more equitable, accessible digestive health solutions. To further accelerate innovation and benefit patients, the American Gastroenterological Association (AGA) and MATTER have launched the first incubator dedicated exclusively to digestive disease care. This initiative will bring together entrepreneurs, researchers, clinicians and industry leaders to accelerate new solutions. https://matter.health/challenges/aga-incubator-improving-gi-care/	Incubator support	Proposal: 9/21/25
		ENERGY SCIENCE (1)		
34.	Critical Technology Challenge: Energy and Sustainability (TechConnect)	The Challenge is an open innovation program focused on accelerating breakthrough technologies in alignment with evolving strategic priorities for national security, infrastructure resilience, and resource efficiency. Areas of interest include: Advanced energy storage systems and battery innovation; Hydrogen, fuel systems, and alternative energy carriers; Carbon management and industrial decarbonization; and Lifecycle and systems-level sustainability solutions. https://www.techconnectworld.com/World2026/CTC_Energy/	Opportunity to pitch at conference in March 2026	Proposal: 10/24/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS (1)		
35.	Enhancing cell therapies with genomic techniques (EU) HORIZON-HLTH-2025-01-TOOL-01	This topic aims at the design of engineered cells to address the current limitations of cellular therapies, such as delivery efficiency, patient safety, in vivo persistence, desired therapeutic effect, immune tolerance and manufacturing workflows. The chosen approach should enable to control the characteristics, fate and function of the engineered cells from gene level onwards and thus lead to customised cells with improved therapeutic features. The use of genetic engineering and in particular gene editing tools should be a key element in the design of the engineered cells. The therapeutic action should be based on the endogenous capabilities of the cells; the exogenous loading of cells with drugs is not in scope. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-TOOL-01	Total funding of €50 million	Proposal: 9/16/25
		HEALTH EQUITY (1)		
36.	Rapid Response: Reinvesting in Racial and Indigenous Health Equity Research (RWJF)	Rapid Response Research funding is exclusively available to applicants who have already received federal funding (e.g., from the NIH, CDC, NSF) for their health equity research, but have since had their funding partially or fully rescinded due to federal administrative actions. We will prioritize research focused on structural solutions to the social determinants of health over those related to specific disease diagnoses or treatment. https://www.rwjf.org/en/grants/active-funding-opportunities/2025/rapid-response-reinvesting-in-racial-and-indigenous-health-equity-research.html	Up to \$200,000, for up to 2 years	Proposal: 10/1/25
		HIV/AIDS (1)		
37.	Forecast: Role of HIV Infection and Chronic Inflammation in Clonal Hematopoiesis (NIH/NHLBI) RFA-HL-27-001	The goals of this NOFO include elucidating the mechanisms by which chronic inflammation and HIV-associated factors as well as other contributing conditions such as aging, cardiovascular diseases, venous thrombosis, chronic obstructive pulmonary disease, and chronic inflammation in general promote CHIP; understanding the global variation in CHIP prevalence among PLWH and individuals affected by other chronic inflammatory, infectious, or age-related conditions; and determining the impact of CHIP on the heart, lung, blood, and sleep (HLBS) health of PLWH and individuals affected by other chronic or systemic conditions. The ultimate goal is to facilitate the development of novel diagnostic and therapeutic strategies to prevent, treat, and potentially cure HLBS conditions initiated and/or accelerated by CHIP in PLWH and individuals affected by other chronic inflammatory, infectious, or age-related conditions. https://www.grants.gov/search-results-detail/360389	TBD	Estimated post date: 4/1/26 Estimated proposal date: 6/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE (13)		
38.	Forecast: Continuing to Enhance Global Health Security: Sustain Efforts and Strategies to Protect and Improve Public Health Globally (CDC/GHC) CDC-RFA-JG-26-0056	This NOFO's main outcomes are to: 1) Improve prevention of avoidable epidemics including naturally occurring outbreaks and intentional or accidental releases of dangerous pathogens; 2) Improve ability to rapidly detect threats early, including detecting characterizing, and reporting emerging biological threats; 3) Responding rapidly and effectively to public health threats of international concern. https://www.grants.gov/search-results-detail/360342	Total funding of \$75 million	Estimated post date: 11/3/25 Estimated proposal date: 1/2/26
39.	Forecast: Enhancing global laboratory systems to safely manage biological risks, deploy diagnostics and sequence pathogens to strengthen health protection worldwide (CDC/GHC) CDC-RFA-JG-26-0058	Activities under this NOFO will focus on protecting and improving public health globally by: 1) strengthening public health laboratory systems; 2) improving public health laboratory workforce; 3) improving bio risk management; 4) reinforcing emergency laboratory preparedness in alignment with 7-1-7 outbreak response paradigm; 5) enhancing laboratory quality management systems and; 6) enhancing diagnostic capacity via rapid tests for low resource settings and genomic sequencing for pathogens of pandemic potential. https://www.grants.gov/search-results-detail/360343	Total funding of \$25 million	Estimated post date: 11/3/25 Estimated proposal date: 1/2/26
40.	Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential (EU) HORIZON-HLTH-2025-01-DISEASE-03	Proposals should exclusively pursue the development of existing antiviral and prophylactic and therapeutic candidates that are based on antibody and/or antibody-derived proteins targeting at least one of the priority viruses: <i>Arenaviridae</i> ; <i>Hantaviridae</i> ; <i>Poxviridae</i> ; <i>Paramyxoviridae</i> ; and <i>Togaviridae</i> . Proposals are expected to conduct preclinical studies of antibodies and antibody-derived proteins, prepare GMP quality test batches and carry out first in human clinical safety studies. Proposals should include a critical discussion of to what extent the antibodies and antibody-derived proteins would be expected to be amenable to production and distribution at a scale sufficient to meet demand in a pandemic. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-DISEASE-03	Total funding of €35 million	Proposal: 9/16/25
41.	Leveraging artificial intelligence for pandemic preparedness and response (EU) HORIZON-HLTH-2025-01-DISEASE-04	The use of AI on diverse datasets, as well as on their combinations within and across disciplines, can greatly increase the accuracy of assessments and predictions of medical (pharmaceutical or non-pharmaceutical) interventions in preparedness for, and response to epidemics and pandemics. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-DISEASE-04	Dependent upon proposal and available funds	Proposal: 9/16/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
44.	Tuberculosis Research Units (Po1 Clinical Trial Optional) (NIH/NIAID) RFA-AI-25-027	The purpose of this notice of funding opportunity (NOFO) is to support the establishment of multidisciplinary TB Research Units (TBRUs) that will operate as a collaborative network to improve understanding of <i>Mycobacterium tuberculosis</i> (Mtb)-host interactions through characterizing the roles of bacterial and host heterogeneity on infection outcomes and disease progression and defining bacterial and host determinants relevant to Mtb establishment, dissemination, and disease stage. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-25-027.html	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 10/7/25 Proposal: 11/7/25
45.	Influenza Transmission Research Consortium (Po1 Clinical Trial Optional) (NIH/NIAID) RFA-AI-25-035	This NOFO aims to support basic research to understand the fundamental mechanisms underlying human-to-human transmission of seasonal influenza virus. The NOFO will establish an Influenza Transmission Research Consortium comprised of a network of individual Influenza Transmission Research Centers. Centers should propose collaborative, multidisciplinary teams that will investigate the dynamics and drivers of influenza transmission and develop novel resources to further the field of respiratory virus transmission. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-25-035.html	Up to \$2.5 million per year, for 5 years	Letter of intent: 10/7/25 Proposal: 11/7/25
46.	I-CREATE Non-Dilutive Funding Solicitation (BARDA/I-CREATE)	Focus areas of interest include new and novel approaches for the detection and diagnosis of pathogens and consequences of biological threats in BARDA's mission space. Examples of technologies I-CREATE is seeking to fund: Diagnostics platforms detection, continuous monitoring, and triaging of infectious disease and biological threats; High-sensitivity, high-specificity, low-cost at-home molecular diagnostics: innovative point-of-need diagnostic platforms for emerging infectious disease and biological threats; Novel pathogen agnostic approaches to infectious disease and biological threats detection; and Low-cost, deployable diagnostics. https://www.universitylabpartners.org/i-create-solicitation	Up to \$200,000, for up to 6 months	Preliminary application: 9/30 Invited proposal: 11/25
47.	Non-Dilutive Funding to Advance Enabling Technologies for Biomanufacturing, Bioanalysis, and Biopharmaceutical Discovery and Development (BARDA/VANGUARD)	BioTools Innovator VANGUARD is seeking breakthrough tools and technologies that enable and accelerate biological research, diagnostics, and therapeutic development. We are especially interested in platforms that improve precision, scalability, reproducibility, or accessibility in life science workflows and clinical care coordination. Areas of interest include: Advanced Assays and Reagents; Drug Candidate Identification Technologies; AI-Based Tools/Algorithms and Automation; Novel Sample Prep, Automation, or Miniaturization Tools; Analytical Platforms applicable to multiple Vaccines/Therapeutic Products; Digital Twin Approaches using Multimodal Clinical Data; Integrated Bioprocess Optimization; and Novel Approaches for Generation of Polyclonal Recombinant Antibodies. https://biotoolsinnovator.org/vanguard-dev/	Up to \$200,000, for up to 6 months	Preliminary application: 9/30 Invited proposal: 1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
48.	Forecast: ASSURE (BARDA/RRPV)	Announcing an upcoming opportunity to partner with BARDA to develop novel immune assays to be able to more broadly assess protective immunity after pathogen exposure and/or vaccine administration. BARDA seeks innovative, multiplexed, high-throughput, scalable and sample sparing assays that can help draw a more comprehensive picture of what constitutes a broad, durable and protective immune response. Beyond antibody titers, this new program will focus on developing assays that can inform on mucosal and cell-mediated immunity and improving sample collection and processing technologies compatible with novel and existing assays. https://www.rpv.org/opportunities/	TBD	Estimated post date: Q4FY25
49.	Forecast: Rapid Antibody Production (BARDA/RRPV)	Antibody development for emerging threat diagnostics is too slow. BARDA is developing a program concept that aims to address this critical bottleneck by funding the R&D and pilot testing of adaptable systems that can fast-track development, screening, and production of antibody or protein binders against biothreats and emerging infectious diseases for use in antigen-based diagnostic tests. https://www.rpv.org/opportunities/	TBD	Estimated post date: Q4FY25 (GMM) Q1FY26 (RFI)
50.	Forecast: Agnostic Diagnostics (BARDA/RRPV)	The Agnostic Diagnostics program will solicit new metagenomic Next Generation Sequencing (mNGS) solutions that are capable of identifying known pathogens. The mNGS device/platform should identify viral and bacterial pathogens utilizing a comprehensive, regulatory-grade database that can quickly be adapted, in collaboration with the FDA, to detect new viral and bacterial pathogens, and initially including either influenza viruses with pandemic potential and other respiratory viral and bacterial pathogens, or PHEMCE biothreats to include <i>Bacillus anthracis</i> , <i>Burkholderia mallei</i> and <i>Burkholderia pseudomallei</i> , filoviruses, <i>Francisella tularensis</i> , <i>Rickettsia prowazekii</i> , <i>Variola virus</i> , and <i>Yersinia pestis</i> . https://www.rpv.org/opportunities/	TBD	TBD
		INTERCEPTION RESEARCH (1)		
51.	NIH Blueprint for Neuroscience: Coordination Center for Interoception Research (BPCCIR) (U24, Clinical Trial Not Allowed) (NIH/NCCIH) RFA-AT-25-004	Impaired interoception is linked to conditions like obesity, diabetes, anxiety, depression, and substance use disorders, which significantly impact the nation's healthcare burden. Advancing interoception research may also lead to innovative strategies for disease prevention and treatment of complex diseases such as Alzheimer's disease, Parkinson's disease, autism, chronic pain, PTSD, IBS, fibromyalgia, and cardiovascular diseases. https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-25-004.html	TBD	Letter of intent: 10/10/25 Proposal: 11/10/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH (1)		
52.	Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders (EU) HORIZON-HLTH-2025-03-DISEASE-02-two-stage	Mental, behavioural and neurodevelopmental disorders, that include for example severe depression, anxiety, schizophrenia, psychosis, PTSD, addictive behaviours, OCD, eating disorders and autism spectrum disorder are a high burden for patients, health systems and society, and remain unmet medical needs. More innovative, safer and more effective therapeutic and relapse-preventing solutions based on active substances are required, as for example for mental disorders many available treatments show modest efficacy, non-negligible side effects, discontinuation problems and high relapse rates. Additionally, other non-invasive multidisciplinary and/or transdiagnostic approaches should be further developed to complement the therapeutic and relapse prevention solutions. These approaches aim to further improve health outcomes, self-determination, autonomy and quality of life in the long-term. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-03-DISEASE-02-two-stage	Total funding of €50 million	Proposal: 9/16/25
		NIH COMMON FUND (2)		
53.	Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed/R01 Basic Experimental Studies with Human Required) (NIH) PAR-25-322 PAR-25-323	Created in 2020, the Katz award provides a unique opportunity for early-stage investigators to take their research in a completely new direction, thereby stimulating innovation and encouraging new approaches to solving problems. This NOFO is appropriate for ESIs who wish to initiate a research project in an area different from their previous research focus and/or training experience, and therefore have not produced preliminary data. https://grants.nih.gov/grants/guide/pa-files/PAR-25-322.html https://grants.nih.gov/grants/guide/pa-files/PAR-25-323.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFOs open through 8/25/28
		PEDIATRIC HEALTH (2)		
54.	Forecast: Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers and Coordinating Center (NIH) RFA-DK-27-121 RFA-DK-27-136	These NOFOs will invite applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use; and for a Research Coordination Center. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. https://www.grants.gov/search-results-detail/360387 https://www.grants.gov/search-results-detail/360441	TBD	Estimated post date: 4/1/26 Estimated proposal date: 12/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		REGENERATIVE MEDICINE (2)		
55.	Advancing Therapeutic Reprogramming for Military Regenerative Medicine (DoD/AFIRM) AFIRM 002	This RPP is focused on supporting regenerative medicine research to improve prevention, detection, diagnosis, treatment, and/or quality of life. Awards made from this effort are intended to support translational research or clinical trials. The six focus areas are: Craniomaxillofacial Regeneration; Extremity Regeneration; Genitourinary/lower abdomen Reconstruction; Skin Regeneration; Ex-vivo/on demand Blood; and Cellular therapies for Trauma and Critical Care. https://afirm.info/proposal-solicitation/	Total funding of \$15 million	White paper: 10/17/25
56.	Advancing cell secretome-based therapies (EU) HORIZON-HLTH-2025-01-TOOL-02	Secretome-based therapies have emerged as a promising alternative to cell-based therapies. The secretome of cells is defined as the repertoire of molecules and biological factors that are secreted into the extracellular space and has been shown to be a key factor for therapeutic activity due to its paracrine effects. The potential to manufacture, store and use secretome factors as off-the-shelf products, while maintaining the therapeutic benefits of cells but with fewer safety concerns, has placed the secretome at the forefront of regenerative medicine. Proposals submitted under this topic should tackle the above-mentioned issues and pave the way to secretome-based therapies that are safe, efficacious, and regulatory-approved for human use. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-TOOL-02	Total funding of €40 million	Proposal: 9/16/25
		RESEARCH SUPPORT (1)		
57.	Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-25-010	This NOFO supports the Nonhuman Primate Reagent Resource (NHPRR) with the goal of ensuring reagent accessibility to the NHP research community. The scope covers two broad categories: 1) development, acquisition, production, and distribution of immunologic reagents; and 2) website, management, and community engagement activities. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-25-010.html	Dependent upon proposal, for up to 5 years	Proposal: 10/28/25
		SMALL BUSINESS DEVELOPMENT (1)		
58.	DoD SBIR 25.4 Release 12 (DoD/CBD) DoD SBIR 2025.4	Topics include: Novel Sampling Tickets for Surface Enhanced Raman Spectroscopy (SERS) of Chemical and Biological (CB) Threat Materials; Integrated Deployable Microsensors for Chemical Detection; Far Forward Manufacturing of CBRN Sensors; Shelf-Stable Nucleic Acid Synthesis Reagents for Field-Deployable Diagnostics; Expeditionary Biologics-on-Demand (BOND); and Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE). https://www.dodsbirsttr.mil/topics-app/	Up to \$209,575, for up to 6 months (Phase I) Up to \$1.397 million, for up to 2 years (D2P2)	Proposal: 10/22/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER (3)		
59.	Forecast: Comprehensive Alcohol Research Centers (P60 Clinical trial Optional) (NIH/NIAAA) RFA-AA-25-012	This NOFO will support an integrated, broad-based multidisciplinary, multi-investigator, long-term program of research and research support activities planned around a specific major research theme. https://www.grants.gov/search-results-detail/360370	TBD	Estimated post date: 11/20/25 Estimated proposal date: 1/21/26
60.	Forecast: Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (NIH/NIDA) RFA-DA-26-058	This NOFO will establish a Center that educates and supports researchers in formal product development for new SUD pharmacotherapeutics. The Center will also help advance the best concepts through initial experiments via technical and financial support. Previous NIDA-supported initiatives in early translational research have shown that drug addiction researchers are eager to acquire formal product development skills and access technical expertise and support. https://www.grants.gov/search-results-detail/360380	Total funding of \$3 million	Estimated post date: 11/21/25 Estimated proposal date: 1/27/26
61.	Forecast: HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center (NIH) RFA-DA-27-006	This initiative will test different implementation strategies and other approaches to address scalability and sustainability of evidence based practices for CP and OUD from a health system perspective. https://www.grants.gov/search-results-detail/360366	Total funding of \$1.75 million	Estimated post date: 1/12/26 Estimated proposal date: 11/2/26
		THERAPEUTICS (2)		
62.	Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections (EU) HORIZON-HLTH-2025-01-DISEASE-01	Proposals should aim to develop phage-based therapies to treat bacterial infections that do not respond to conventional treatment options. For this, applicants should carry out multicenter, multinational randomised controlled clinical trial (RCT) to generate scientific evidence demonstrating safety and efficacy of phage-based therapy as stand-alone or in combination with standard-of-care (such as antibiotic or other innovative non-antibiotic-based treatment) for the treatment of difficult-to-treat bacterial infections. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-DISEASE-01	Total funding of €45 million	Proposal: 9/16/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS		
63.	Awards for Development, Evaluation, and Validation of Innovative Therapeutics Solutions (BARDA/VITAL)	The VITAL Hub seeks proposals for the development of innovative therapeutics solutions in alignment with BARDA’s mission to promote health security. We are seeking product development-focused solutions in the following topic areas: Targeting therapeutics; Activating the innate immune system; and Promoting rapid recovery from radiological and nuclear threats. https://vitalhubhealth.com/dev-awards/	Up to \$200,000, for up to 6 months	Pre-proposal: 9/26/25 Invited proposal Fall 2025



Recurring Opportunities

September 10, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
64.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/opp/c575f73500844322be760e0d98c233ac/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
65.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/opp/173be613d10249d8b0096c649e5203b8/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
66.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/opp/d85f2223a88442f3ba6eedf9a0629775/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
67.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/opp/ca0ae33ab9544686b47788025c67cca2/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
68.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/4caa8d320fb24050b389fe721296a13d/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
69.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The BM&P Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fadbd41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White paper: 10/28/28
70.	Research Interests of the Air Force Office of Scientific Research FA9550-25-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological nature by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://www.grants.gov/search-results-detail/359050	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
71.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (9)		
72.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
73.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
74.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
75.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
76.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; view the full list of research topics . https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
77.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
78.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
79.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
80.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-c0bea38cd0b1	Dependent upon proposal	White papers accepted through 12/31/2030
81.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/fca6a4b42ff94fd5892fdae9799941f/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
82.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/d832248e72e14c3c8cee96ee3c8b2170/view	Dependent upon proposal	Proposal: 9/25/28
83.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e50bdd00a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
84.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/5fff3c4c76c341a4a6b1d2010211c793/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 10/9/25
85.	Defense Sciences Office, Office-wide HR001125S0013	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/c3f0bedbf22c4e2daf5bbo713f4ce4a/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/2/26
		DEFENSE THREAT REDUCTION AGENCY (4)		
86.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY		
87.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
88.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
89.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034
		DEPARTMENT OF ENERGY (1)		
90.	FY 2025 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003432	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature's mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/356590	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION (2)		
91.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 24-579	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the full list of topics. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-0/nsf24-579/solicitation	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis through 11/5/25.
92.	NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs (SBIR-STTR Fast-Track) NSF 24-582	The NSF SBIR/STTR Fast-Track programs provide non-dilutive, fixed amount cooperative agreements for the development of a broad range of technologies based on discoveries in science and engineering with the potential for societal and economic impacts. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation	Up to \$1,555,000, for up to 3 years	Project pitches accepted on a rolling basis through 11/5/25. Proposal: 11/5/25
		NAVY (3)		
93.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.onr.navy.mil/work-with-us/funding-opportunities/fy25-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/25
94.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/1ee082f371ab449294aco84bb06ba6co/view	Dependent upon proposal and award mechanism	White papers accepted through 9/30/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
95.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (7)		
96.	Phased Large Awards for Comparative Effectiveness Research -- Cycle 3 2025	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. Applications must address at least one of the National Priorities for Health. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-3-2025	Up to \$22 million, for up to 6.5 years	Letter of intent: 9/23/25 Proposal: 1/13/26
97.	Broad Pragmatic Studies Funding Announcement -- Cycle 3 2025	This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of twelve topic themes, based on how their proposed research aligns with the themes. Cycle 3 SAEs include: Social Isolation and Loneliness in Older Adults, Health Communication Strategies for Uptake of COVID-19 Vaccine, and Promoting Sleep Health in Inpatient Settings. https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-3-2025	Up to \$12 million, for up to 5 years Dependent upon award mechanism	Letter of intent: 9/23/25 Proposal: 1/13/26
98.	Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 3 2025	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-3-2025	Up to \$1.5 million, for up to 3 years	Letter of intent: 9/23/25 Proposal: 1/13/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
99.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 3 2025	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-3-2025	Up to \$750,000, for up to 3 years	Letter of intent: 9/23/25 Proposal: 1/13/26
100.	Engagement Award: Capacity Building -- Fall 2025 Cycle	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-fall-2025-cycle	Up to \$300,000, for up to 2 years	Letter of intent: 9/29/25 Proposal: 1/12/26
101.	Engagement Award: Stakeholder Convening Support -- Fall 2025 Cycle	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-convening-support-fall-2025-cycle	Up to \$125,000, for up to 1 year	Letter of intent: 9/29/25 Proposal: 1/12/26
102.	Engagement Award: Dissemination Initiative -- Fall 2025 Cycle	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-fall-2025-cycle	Up to \$300,000, for up to 2 years	Letter of intent: 9/29/25 Proposal: 1/12/26





Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

GBG Acronyms

Updated Monthly

September 10, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIHES: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:

<https://uso6web.zoom.us/j/82298749878?pwd=IAQylo5Ga28qBhspmDmx5yvyxDobcw.1>

Meeting ID: 822 9874 9878

Passcode: 394902

